USFDA assigns VAI classification to Jubilant Pharmova's API facility at Nanjangud

Jubilant Pharmova Limited today announced that, pursuant to the United States Food and Drug Administration (USFDA) inspection of its API manufacturing facility at Nanjangud during 05-13 December 2022, it received a communication from the USFDA through which the regulatory agency assigned the inspection classification of the API facility as "Voluntary Action Indicated (VAI)".

Based on this inspection and the USFDA VAI classification, this facility is in compliance with regard to current good manufacturing practices (cGMP).

Shares of Jubilant Pharmova Limited was last trading in BSE at Rs. 311.50 as compared to the previous close of Rs. 304.15. The total number of shares traded during the day was 13792 in over 735 trades.

The stock hit an intraday high of Rs. 325.40 and intraday low of 298.35. The net turnover during the day was Rs. 4238450.00.

Source : Equity Bulls

Keywords

JubilantPharmova INE700A01033 USFDA VAI ManufacturingFacility Nanjangud